Showing results (331-340 of 419) with videos related to

Sort By:
Pageof 42
Diagnosis (Berlin, Germany)|August 1, 2024
Bridging the divide: addressing discrepancies between clinical guidelines, policy guidelines, and biomarker utilizationDenis Horgan, Paul Hofman, Reinhard Buttner, et al.
European Journal of Cancer (Oxford, England : 1990)|January 10, 2025
A first-in-human phase 1/2 dose-escalation study of MAK683 (EED inhibitor) in patients with advanced malignanciesVincent Ribrag, Lara Iglesias, Filippo De Braud, et al.
NPJ Precision Oncology|April 18, 2023
Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignanciesOmar Alhalabi, Roman Groisberg, Ralph Zinner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2023
Clinico-Genomic Profiling of Conventional and Dedifferentiated Chondrosarcomas Reveals TP53 Mutation to Be Associated with Worse OutcomesRyan A Denu, Richard K Yang, Alexander J Lazar, et al.
Oncotarget|September 3, 2016
Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancyHaeseong Park, Ignacio Garrido-Laguna, Aung Naing, et al.
JCO Precision Oncology|September 14, 2020
Targeting ERBB2 (HER2) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional IndicationsEcaterina E Ileana Dumbrava, Kavitha Balaji, Kanwal Raghav, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 24, 2018
BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET StudyThomas Kaley, Mehdi Touat, Vivek Subbiah, et al.
Oncotarget|May 28, 2015
Clinical next generation sequencing to identify actionable aberrations in a phase I programGenevieve M Boland, Sarina A Piha-Paul, Vivek Subbiah, et al.
Oncotarget|April 19, 2014
MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unitDenis L Fontes Jardim, Debora de Melo Gagliato, Gerald S Falchook, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 2, 2022
Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101)Hani Babiker, Erkut Borazanci, Vivek Subbiah, et al.
Pageof 42